Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06333496
Other study ID # AB20240102H
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2, 2024
Est. completion date April 8, 2024

Study information

Verified date April 2024
Source Alpine Biotech LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date April 8, 2024
Est. primary completion date March 29, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Volunteers must be over the age of 18. - Volunteers cannot be smokers. - Volunteers cannot be currently taking a dietary supplement or prescription for weight loss. - Exercising volunteers must maintain their regimen consistently throughout the course of the 12-week study. - Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 12-week study. - Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9 Exclusion Criteria: - Female volunteers who are pregnant or planning to become pregnant within the next three months. - Volunteers who are taking any stimulant medications (e.g. Adderall, Adzenys, Dexedrine, Ritalin, Methylphenidate, etc).

Study Design


Intervention

Dietary Supplement:
GLP1 Booster (GB)
GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, White kidney bean (Phaseolus vulgaris) extract, berberine (from Berberis aristata bark extract), and chromium (III) an essential trace mineral. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.

Locations

Country Name City State
United States Alpine Bio Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Alpine Biotech LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary blood glucose level 12 week
Primary blood HbA1c level 12 week
Primary blood insulin level 12 week
Primary blood GLP1 level 12 week
Primary blood cholesterol level 12 week
Primary body weight 12 week
Primary body fat mass 12 week
Primary body lean mass 12 week
Primary body mass index 12 week
Primary body fat index 12 week
Primary waist hip ratio 12 week
Secondary Satiety score 12 week
Secondary Resting metabolic rate 12 week
Secondary Blood pressure both systolic and diastolic pressures 12 week
Secondary Heart rate 12 week
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2